Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Cyclacel Pharmaceuticals Says David Lazar Buys $3.1 Million in Preferred Stock, Becomes Interim CEO

In This Article:

Cyclacel Pharmaceuticals (CYCC) said investor David Lazar agreed to buy $3.1 million in preferred st

Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.